• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Gryska David W

    6/16/25 4:30:04 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GRYSKA DAVID W

    (Last) (First) (Middle)
    C/O MIND MEDICINE (MINDMED) INC.
    ONE WORLD TRADE CENTER, SUITE 8500

    (Street)
    NEW YORK NY 10007

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mind Medicine (MindMed) Inc. [ MNMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $7.3 06/12/2025 A 75,187 (1) 06/11/2035 Common Shares 75,187 $0 75,187 D
    Explanation of Responses:
    1. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
    /s/ Mark Sullivan, Attorney-in-Fact for David W Gryska 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    12/9/2022$25.00Buy
    ROTH Capital
    More analyst ratings

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed Announces New Employee Inducement Grants

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the applicable employee's respective start date. The Options have an exercise price equal to the closing price of MindMed's common shares on the last trading day on which MindMed's common shares traded prior to the date of the respective

      6/9/25 4:01:00 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Participate in June Investor Conferences

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Presentation Date and Time: Thursday, June 5, 2025 at 12:50 PM ET Location: New York, NY Webcast Link: Jefferies Global Healthcare Conference H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Format: Pre-recorded Fireside Chat Date and Time: Tuesday, June 17, 2025 at 7:00 AM ET Location: Virtual We

      5/28/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD

      5/27/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    SEC Filings

    See more
    • SEC Form S-8 filed by Mind Medicine (MindMed) Inc.

      S-8 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      6/20/25 4:05:51 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      6/16/25 5:00:10 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/27/25 7:30:20 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      12/5/24 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/26/24 7:00:03 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/20/24 9:14:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care